Drugs & Therapy Perspectives

, Volume 8, Issue 10, pp 1–6 | Cite as

HIV protease inhibitors: an important advance

New Drugs and Therapeutic


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Saquinavir mesylate monograph. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 47–54Google Scholar
  2. 2.
    Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12PubMedCrossRefGoogle Scholar
  3. 3.
    Indinavir sulfate. AHFS Drug Information 96. Current developments. Bethesda: American Society of Hospital Pharmacists, 1996: 24–28Google Scholar
  4. 4.
    Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct; 52(4): 541–9PubMedCrossRefGoogle Scholar
  5. 5.
    Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996 Jul; 52(1): 93–112PubMedCrossRefGoogle Scholar
  6. 6.
    New drugs for HIV infection. Med Lett 1996 Apr 12; 38(972): 35–7Google Scholar
  7. 7.
    Merck Crixivan temporary distribution to begin filling scripts March 25 through independent pharmacy service; scale-up facilities to be ready in six months. The Pink Sheet, FDC Reports 1996 Mar 18: 4Google Scholar
  8. 8.
    Swift US approval for Abbott’s Norvir. Scrip 1996 Mar 8; (2109): 17Google Scholar
  9. 9.
    Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996 Jul 10; 276(2): 146–56PubMedCrossRefGoogle Scholar
  10. 10.
    Merck’s Crixivan recommended for US approval. Scrip 1996 Mar 8; (2109): 18Google Scholar
  11. 11.
    Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res 1996; 29: 91–3PubMedCrossRefGoogle Scholar
  12. 12.
    Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir; update [abstract]. XI International Conference on AIDS; 1996 Jul 7; VancouverGoogle Scholar
  13. 13.
    Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011–7PubMedCrossRefGoogle Scholar
  14. 14.
    Bleeding warnings for protease inhibitors. Scrip 1996 Jul 26; (2149): 17Google Scholar
  15. 15.
    Norvir capsules and solution. Pharm J 1996 Sep 7; 257: 330Google Scholar
  16. 16.
    New data on protease inhibitors from Vancouver. Scrip 1996 Jul 23; (2148): 17Google Scholar
  17. 17.
    Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage [abstract no. LB-5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 8Google Scholar
  18. 18.
    Lamivudine and stavudine: useful additions to the available nucleoside analogues. Drug Ther Perspect 1996 Oct 14; 8(8): 1–6CrossRefGoogle Scholar
  19. 19.
    Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. PharmacoEconomics 1996 Aug;10(2): 109–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Personalised recommendations